Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Aug 14;359(7):697-708.
doi: 10.1056/NEJMoa0800743.

The effects of tibolone in older postmenopausal women

Steven R Cummings  1 , Bruce Ettinger, Pierre D Delmas, Peter Kenemans, Victoria Stathopoulos, Pierre Verweij, Mirjam Mol-Arts, Lenus Kloosterboer, Lori Mosca, Claus Christiansen, John Bilezikian, Eduardo Mario Kerzberg, Susan Johnson, Jose Zanchetta, Diederich E Grobbee, Wilfried Seifert, Richard Eastell; LIFT Trial Investigators
Collaborators, Affiliations
Randomized Controlled Trial

The effects of tibolone in older postmenopausal women

Steven R Cummings et al. N Engl J Med. .

Abstract

Background: Tibolone has estrogenic, progestogenic, and androgenic effects. Although tibolone prevents bone loss, its effects on fractures, breast cancer, and cardiovascular disease are uncertain.

Methods: In this randomized study, we assigned 4538 women, who were between the ages of 60 and 85 years and had a bone mineral density T score of -2.5 or less at the hip or spine or a T score of -2.0 or less and radiologic evidence of a vertebral fracture, to receive once-daily tibolone (at a dose of 1.25 mg) or placebo. Annual spine radiographs were used to assess for vertebral fracture. Rates of cardiovascular events and breast cancer were adjudicated by expert panels.

Results: During a median of 34 months of treatment, the tibolone group, as compared with the placebo group, had a decreased risk of vertebral fracture, with 70 cases versus 126 cases per 1000 person-years (relative hazard, 0.55; 95% confidence interval [CI], 0.41 to 0.74; P<0.001), and a decreased risk of nonvertebral fracture, with 122 cases versus 166 cases per 1000 person-years (relative hazard, 0.74; 95% CI, 0.58 to 0.93; P=0.01). The tibolone group also had a decreased risk of invasive breast cancer (relative hazard, 0.32; 95% CI, 0.13 to 0.80; P=0.02) and colon cancer (relative hazard, 0.31; 95% CI, 0.10 to 0.96; P=0.04). However, the tibolone group had an increased risk of stroke (relative hazard, 2.19; 95% CI, 1.14 to 4.23; P=0.02), for which the study was stopped in February 2006 at the recommendation of the data and safety monitoring board. There were no significant differences in the risk of either coronary heart disease or venous thromboembolism between the two groups.

Conclusions: Tibolone reduced the risk of fracture and breast cancer and possibly colon cancer but increased the risk of stroke in older women with osteoporosis. (ClinicalTrials.gov number, NCT00519857.)

PubMed Disclaimer

Figures

Figure 1
Figure 1. Percent Changes in Bone Mineral Density and Cumulative Proportions of Patients with Nonvertebral Fractures
Panel A shows the percent changes in bone mineral density at the lumbar spine and femoral neck in the two study groups after 4 years. The differences between the tibolone group and the placebo group were significant (P<0.001) at each year. The I bars denote 95% confidence intervals. Panel B shows the cumulative proportions of patients in the two groups with nonvertebral fractures (relative hazard in the tibolone group, 0.75; 95% CI, 0.58 to 0.93).
Figure 2
Figure 2. Cumulative Percentages of Patients with Breast Cancer and Stroke
At 4 years, therapy with tibolone was associated with a decrease in the risk of invasive breast cancer (relative hazard, 0.32; 95% CI, 0.13 to 0.80; P=0.02) (Panel A) but with an increase in the risk of stroke (relative hazard, 2.19; 95% CI, 1.14 to 4.23; P=0.02) (Panel B).
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids. 2003;68:21–30. - PubMed
    1. Jelinek J, Kappen A, Schönbaum E, Lomax P. A primate model of human postmenopausal hot flushes. J Clin Endocrinol Metab. 1984;59:1224–8. - PubMed
    1. Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas. 2005;50:222–30. - PubMed
    1. Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab. 1996;81:2419–22. - PubMed
    1. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab. 2001;86:4717–26. - PubMed

Publication types

MeSH terms

Associated data